Top

Current Oncology Reports

Published in:

01-09-2018 | Lung Cancer (H Borghaei, Section Editor)

The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring

Authors: Jillian Wilhelmina Paulina Bracht, Clara Mayo-de-las-Casas, Jordi Berenguer, Niki Karachaliou, Rafael Rosell

Published in: Current Oncology Reports | Issue 9/2018

Abstract

Purpose of Review

Liquid biopsies have potential as tools for diagnosis, prognosis, and prediction of response to therapy. Herein, we will extensively review four liquid biosources, tumor-educated platelets (TEPs), cell-free DNA (cfDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) and we will clarify their optimal application in non-small cell lung cancer (NSCLC) diagnosis and therapy.

Recent Findings

Liquid biopsies are a minimally invasive alternative to tissue biopsies—especially important in NSCLC patients—since tumor tissue is often unavailable or insufficient for complete genetic analysis. The main advantages of liquid biopsies include the possibility for repeated sampling, the lower cost, and the fact that they can reflect the complete molecular status of the patient better than a single-site biopsy. This is specifically important for lung adenocarcinoma patients since the detection of specific genetic alterations can predict response to targeted therapies.

Summary

Molecular analysis is currently cardinal for therapy decision-making and disease monitoring in lung cancer patients. Liquid biopsies can make easier our daily clinical practice and if prospectively tested and validated may serve as a means for lung cancer early detection.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.PubMedCrossRef

Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. https://doi.org/10.1016/S0140-6736(16)30958-8.PubMedCrossRef

Karachaliou N, Sosa AE, Barron FB, Gonzalez Cao M, Santarpia M, Rosell R. Pharmacological management of relapsed/refractory NSCLC with chemical drugs. Expert Opin Pharmacother. 2017;18:1–10. https://doi.org/10.1080/14656566.2017.1285284.CrossRef

Rosell R, Karachaliou N. Large-scale screening for somatic mutations in lung cancer. Lancet. 2016;387(10026):1354–6. https://doi.org/10.1016/S0140-6736(15)01125-3.PubMedCrossRef

Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7(6):596–609. https://doi.org/10.1158/2159-8290.CD-16-1337.PubMedPubMedCentralCrossRef

• Karachaliou N, Sosa AE, Molina MA, Centelles Ruiz M, Rosell R. Possible application of circulating free tumor DNA in non-small cell lung cancer patients. J Thorac Dis. 2017;9(Suppl 13):S1364–S72. https://doi.org/10.21037/jtd.2017.09.59. The SLIPP study was used to compare the performance of the Guardant360 NGS panel in detecting genetic alterations in ctDNA versus standard of care tissue testing. Blood and tissue samples from metastatic non-squamous NSCLC patients were collected before first-line chemotherapy and upon progression. PubMedPubMedCentralCrossRef

Senan S, Paul MA, Lagerwaard FJ. Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy? Lancet Oncol. 2013;14(7):e270–4. https://doi.org/10.1016/S1470-2045(12)70592-2.PubMedCrossRef

Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. preventive services task force recommendation. Ann Intern Med. 2016;164(4):244–55. https://doi.org/10.7326/M15-0969.PubMedCrossRef

Weller DP, Patnick J, McIntosh HM, Dietrich AJ. Uptake in cancer screening programmes. Lancet Oncol. 2009;10(7):693–9. https://doi.org/10.1016/S1470-2045(09)70145-7.PubMedCrossRef

10.

Budenholzer B. Screening for colorectal cancer. Lancet. 1997;349(9048):356–7; author reply 8. https://doi.org/10.1016/S0140-6736(05)62855-3.PubMedCrossRef

11.

Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35. https://doi.org/10.1016/S0140-6736(14)60525-0.PubMedPubMedCentralCrossRef

12.

Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–40. https://doi.org/10.1038/bjc.2013.177.PubMedPubMedCentralCrossRef

13.

Karachaliou N, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R. Real-time liquid biopsies become a reality in cancer treatment. Ann Transl Med. 2015;3(3):36. https://doi.org/10.3978/j.issn.2305-5839.2015.01.16. PubMedPubMedCentralCrossRef

14.

Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–48. https://doi.org/10.1038/nrclinonc.2017.14.PubMedCrossRef

15.

Friedrich MJ. Going with the flow: the promise and challenge of liquid biopsies. JAMA. 2017;318(12):1095–7. https://doi.org/10.1001/jama.2017.10203.PubMedCrossRef

16.

Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, et al. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Biophys Acta. 2014;1846(2):539–46. https://doi.org/10.1016/j.bbcan.2014.10.001.PubMedCrossRef

17.

•• Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018; https://doi.org/10.1126/science.aar3247. This study describes a new multi-analyte blood test based on cfDNA and circulating proteins—called CellSEEK—that may be used to detect and localize surgically resectable cancers.

18.

•• Best MG, Sol N, In ’t Veld S, Vancura A, Muller M, Niemeijer AN, et al. Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets. Cancer Cell. 2017;32(2):238–52 e9. https://doi.org/10.1016/j.ccell.2017.07.004. In this paper, a Particle-Swarm Optimization algorithm—trained on TEP mRNA from healthy individuals and NSCLC patients—was shown to be able to distinguish between NSCLC patients and healthy controls with an accuracy of 81 and 88% in early- and late-stage NSCLC patients respectively. PubMedCrossRefPubMedCentral

19.

• Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell. 2015;28(5):666–76. https://doi.org/10.1016/j.ccell.2015.09.018. The study demonstrates that TEP mRNA-seq analysis can be used to train a LOOCV SVM algorithm, which can then distinguish between the blood of healthy individuals and cancer patients with an accuracy of 96%. PubMedPubMedCentralCrossRef

20.

Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4(6):650–61. https://doi.org/10.1158/2159-8290.CD-13-1014.PubMedPubMedCentralCrossRef

21.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. https://doi.org/10.1126/scitranslmed.3007094.PubMedPubMedCentralCrossRef

22.

Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–86. https://doi.org/10.1200/JCO.2012.45.2011.PubMedPubMedCentralCrossRef

23.

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–50.PubMed

24.

Calabuig-Farinas S, Jantus-Lewintre E, Herreros-Pomares A, Camps C. Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win? Transl Lung Cancer Res. 2016;5(5):466–82. https://doi.org/10.21037/tlcr.2016.10.02.PubMedPubMedCentralCrossRef

25.

Sanchez-Cespedes M, Monzo M, Rosell R, Pifarre A, Calvo R, Lopez-Cabrerizo MP, et al. Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol. 1998;9(1):113–6.PubMedCrossRef

26.

Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999;59(1):67–70.PubMed

27.

Ramirez JL, Sarries C, de Castro PL, Roig B, Queralt C, Escuin D, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. 2003;193(2):207–16.PubMedCrossRef

28.

Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Penas R, et al. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: the Spanish lung Cancer group. J Clin Oncol. 2005;23(36):9105–12. https://doi.org/10.1200/JCO.2005.02.2905.PubMedCrossRef

29.

• Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol. 2015;1(2):149–57. https://doi.org/10.1001/jamaoncol.2014.257. The EGFR L858R mutation was investigated in cfDNA and associated with survival in patients participating in a NSCLC trial comparing efficacy of erlotinib versus chemotherapy. PubMedCrossRef

30.

Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem. 2006;52(10):1833–42. https://doi.org/10.1373/clinchem.2005.062893.PubMedCrossRef

31.

Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung Cancer. JAMA Oncol. 2016;2(8):1014–22. https://doi.org/10.1001/jamaoncol.2016.0173.PubMedPubMedCentralCrossRef

32.

Chen T, He R, Hu X, Luo W, Hu Z, Li J, et al. Circulating tumor DNA: a potential biomarker from solid tumors’ monitor to anticancer therapies. Cancer Transl Med. 2017;3(2):64–7. https://doi.org/10.4103/ctm.ctm_6_17.CrossRef

33.

Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res. 2002;22(1A):421–5.PubMed

34.

Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem. 2003;49(6 Pt 1):1028–9.PubMedCrossRef

35.

Heitzer E, Auer M, Ulz P, Geigl JB, Speicher MR. Circulating tumor cells and DNA as liquid biopsies. Genome Med. 2013;5(8):73. https://doi.org/10.1186/gm477. PubMedPubMedCentralCrossRef

36.

Kohn L, Johansson M, Grankvist K, Nilsson J. Liquid biopsies in lung cancer-time to implement research technologies in routine care? Ann Transl Med. 2017;5(13):278. https://doi.org/10.21037/atm.2017.04.12.PubMedPubMedCentralCrossRef

37.

Sorber L, Zwaenepoel K, Deschoolmeester V, Van Schil PE, Van Meerbeeck J, Lardon F, et al. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer. 2017;107:100–7. https://doi.org/10.1016/j.lungcan.2016.04.026. PubMedCrossRef

38.

Vendrell JA, Mau-Them FT, Beganton B, Godreuil S, Coopman P, Solassol J. Circulating cell free tumor DNA detection as a routine tool for lung cancer patient management. Int J Mol Sci. 2017;18(2) https://doi.org/10.3390/ijms18020264.

39.

Perez-Callejo D, Romero A, Provencio M, Torrente M. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res. 2016;5(5):455–65. https://doi.org/10.21037/tlcr.2016.10.07.PubMedPubMedCentralCrossRef

40.

Zhang BO, Xu CW, Shao Y, Wang HT, Wu YF, Song YY, et al. Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation. Exp Ther Med. 2015;9(4):1383–8. https://doi.org/10.3892/etm.2015.2221.PubMedPubMedCentralCrossRef

41.

Worrillow L, Baskaran P, Care MA, Varghese A, Munir T, Evans PA, et al. An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases. Oncogene. 2016;35(40):5328–36. https://doi.org/10.1038/onc.2016.73.PubMedCrossRef

42.

Cai X, Janku F, Zhan Q, Fan JB. Accessing genetic information with liquid biopsies. Trends Genet. 2015;31(10):564–75. https://doi.org/10.1016/j.tig.2015.06.001.PubMedCrossRef

43.

•• Lin E, Rivera-Baez L, Fouladdel S, Yoon HJ, Guthrie S, Wieger J, et al. High-throughput microfluidic labyrinth for the label-free isolation of circulating tumor cells. Cell Syst. 2017;5(3):295–304 e4. https://doi.org/10.1016/j.cels.2017.08.012. The authors describe a new label-free CTC isolation method, with highest purity among other label-free methods. The blood flows through a labyrinth device with loops and corners to separate different cell types and isolate CTCs. PubMedCrossRef

44.

Yu Y, Chen Z, Dong J, Wei P, Hu R, Zhou C, et al. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol. 2013;6(6):697–702.PubMedPubMedCentralCrossRef

45.

Ntouroupi TG, Ashraf SQ, McGregor SB, Turney BW, Seppo A, Kim Y, et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer. 2008;99(5):789–95. https://doi.org/10.1038/sj.bjc.6604545.PubMedPubMedCentralCrossRef

46.

Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer. 2012;130(7):1590–7. https://doi.org/10.1002/ijc.26111.PubMedCrossRef

47.

Hofman V, Long E, Ilie M, Bonnetaud C, Vignaud JM, Flejou JF, et al. Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology. 2012;23(1):30–8. https://doi.org/10.1111/j.1365-2303.2010.00835.x.PubMedCrossRef

48.

Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012;18(8):2391–401. https://doi.org/10.1158/1078-0432.CCR-11-3148.PubMedCrossRef

49.

Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014;20(6):1698–705. https://doi.org/10.1158/1078-0432.CCR-13-2482.PubMedPubMedCentralCrossRef

50.

•• Mayo-de-las-Casas C, Jordana-Ariza N, Garzon-Ibanez M, Balada-Bel A, Bertran-Alamillo J, Viteri-Ramirez S, et al. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions. Ann Oncol. 2017;0:1–8. https://doi.org/10.1093/annonc/mdx288. Often tumor tissue if unavailable or insufficient for genetic analysis. Therefore, this study investigated the use of cfDNA as a surrogate for tumor tissue to select patients for the treatment with EGFR-TKIs. CrossRef

51.

• Malapelle U, Mayo de-Las-Casas C, Rocco D, Garzon M, Pisapia P, Jordana-Ariza N, et al. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. Br J Cancer. 2017;116(6):802–10. https://doi.org/10.1038/bjc.2017.8. A gene panel (“SiRe”) based on ultra-deep sequencing of ctDNA was created to detect 568 mutations in six different genes involved in NSCLC, with sensitivity and analytical specificity of 90.5 and 100%, respectively. PubMedPubMedCentralCrossRef

52.

Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9(9):1345–53. https://doi.org/10.1097/JTO.0000000000000263.PubMedPubMedCentralCrossRef

53.

Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883–9. https://doi.org/10.1093/annonc/mdv270.PubMedCrossRef

54.

Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung Cancer: the ASPIRATION study. JAMA Oncol. 2016;2(3):305–12. https://doi.org/10.1001/jamaoncol.2015.4921.PubMedCrossRef

55.

Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643–52. https://doi.org/10.1016/S1470-2045(16)30508-3.PubMedCrossRef

56.

Mok T, Ladrera G, Srimuninnimit V, Sriuranpong V, Yu CJ, Thongprasert S, et al. Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. Lung Cancer. 2016;98:1–8. https://doi.org/10.1016/j.lungcan.2016.04.023. PubMedCrossRef

57.

Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One. 2015;10(10):e0140712. https://doi.org/10.1371/journal.pone.0140712.PubMedPubMedCentralCrossRef

58.

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91. https://doi.org/10.1056/NEJMoa040766.PubMedCrossRef

59.

Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2012;7(2):306–15. https://doi.org/10.1097/JTO.0b013e31823c5c16.PubMedCrossRef

60.

Alix-Panabieres C, Pantel K. Characterization of single circulating tumor cells. FEBS Lett. 2017;591(15):2241–50. https://doi.org/10.1002/1873-3468.12662.PubMedCrossRef

61.

Larrea E, Sole C, Manterola L, Goicoechea I, Armesto M, Arestin M, et al. New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci. 2016;17(5) https://doi.org/10.3390/ijms17050627.

62.

Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev. 2010;20(1):96–9. https://doi.org/10.1016/j.gde.2009.12.002.PubMedPubMedCentralCrossRef

63.

Negin BP, Cohen SJ. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options in Oncol. 2010;11(1–2):1–13. https://doi.org/10.1007/s11864-010-0115-3.CrossRef

64.

Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM. Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Mol Diagn Ther. 2014;18(4):389–402. https://doi.org/10.1007/s40291-014-0101-8.PubMedPubMedCentralCrossRef

65.

Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366–77. https://doi.org/10.1056/NEJMoa0800668.PubMedPubMedCentralCrossRef

66.

Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29(12):1556–63. https://doi.org/10.1200/JCO.2010.28.7045.PubMedCrossRef

67.

Juan O, Vidal J, Gisbert R, Munoz J, Macia S, Gomez-Codina J. Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine. Clin Transl Oncol. 2014;16(7):637–43. https://doi.org/10.1007/s12094-013-1128-8.PubMedCrossRef

68.

Dorsey JF, Kao GD, MacArthur KM, Ju M, Steinmetz D, Wileyto EP, et al. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results. Cancer. 2015;121(1):139–49. https://doi.org/10.1002/cncr.28975. PubMedCrossRef

69.

Rolle A, Gunzel R, Pachmann U, Willen B, Hoffken K, Pachmann K. Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse: a preliminary report. World J Surg Oncol. 2005;3(1):18. https://doi.org/10.1186/1477-7819-3-18. PubMedPubMedCentralCrossRef

70.

George JN. Platelets. Lancet. 2000;355(9214):1531–9. https://doi.org/10.1016/S0140-6736(00)02175-9.PubMedCrossRef

71.

Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol. 2002;3(7):425–30.PubMedCrossRef

72.

Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014;33(1):231–69. https://doi.org/10.1007/s10555-014-9498-0.PubMedPubMedCentralCrossRef

73.

McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16(8):717–27. https://doi.org/10.1038/ncb3015.PubMedCrossRefPubMedCentral

74.

Nilsson RJ, Balaj L, Hulleman E, van Rijn S, Pegtel DM, Walraven M, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood. 2011;118(13):3680–3. https://doi.org/10.1182/blood-2011-03-344408.PubMedCrossRefPubMedCentral

75.

• Nilsson RJ, Karachaliou N, Berenguer J, Gimenez-Capitan A, Schellen P, Teixido C, et al. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget. 2016;7(1):1066–75. https://doi.org/10.18632/oncotarget.6279. The EML4-ALK rearrangement can be found in blood platelets of NSCLC patients. Moreover, it was possible to predict therapy resistance based on blood platelet analysis, 2 months before this could be seen radiographically. PubMedCrossRef

76.

Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science. 2010;328(5978):562–4. https://doi.org/10.1126/science.328.5978.562. PubMedCrossRef

77.

Hoffman M, Monroe DM, Roberts HR. A rapid method to isolate platelets from human blood by density gradient centrifugation. Am J Clin Pathol. 1992;98(5):531–3.PubMedCrossRef

78.

Mustard JF, Kinlough-Rathbone RL, Packham MA. Isolation of human platelets from plasma by centrifugation and washing. Methods Enzymol. 1989;169:3–11.PubMedCrossRef

79.

Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470–6. https://doi.org/10.1038/ncb1800.PubMedPubMedCentralCrossRef

80.

Reclusa P, Taverna S, Pucci M, Durendez E, Calabuig S, Manca P, et al. Exosomes as diagnostic and predictive biomarkers in lung cancer. J Thorac Dis. 2017;9(Suppl 13):S1373–S82. https://doi.org/10.21037/jtd.2017.10.67. PubMedPubMedCentralCrossRef

81.

•• Nabet BY, Qiu Y, Shabason JE, Wu TJ, Yoon T, Kim BC, et al. Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in Cancer. Cell. 2017;170(2):352–66 e13. https://doi.org/10.1016/j.cell.2017.06.031. The study describes the analysis of specific exosome-derived RNAs, which were shown to promote tumor growth and induce therapy resistance in breast cancer patients. Moreover, the RNA isolated from exosomes may be used as a diagnostic biomarker for cancer. PubMedCrossRefPubMedCentral

82.

Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–83. https://doi.org/10.1083/jcb.201211138.PubMedPubMedCentralCrossRef

83.

Munson P, Shukla A. Exosomes: potential in cancer diagnosis and therapy. Medicines (Basel). 2015;2(4):310–27. https://doi.org/10.3390/medicines2040310.CrossRef

84.

Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, et al. Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res. 2017;23(17):5311–9. https://doi.org/10.1158/1078-0432.CCR-17-0577.PubMedCrossRef

85.

Jakobsen KR, Paulsen BS, Baek R, Varming K, Sorensen BS, Jorgensen MM. Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma. J Extracell Vesicles. 2015;4:26659. https://doi.org/10.3402/jev.v4.26659.PubMedCrossRef

86.

Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014;24(6):766–9. https://doi.org/10.1038/cr.2014.44.PubMedPubMedCentralCrossRef

87.

National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. https://doi.org/10.1056/NEJMoa1102873. CrossRef

88.

Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax. 2012;67(4):296–301. https://doi.org/10.1136/thoraxjnl-2011-200736.PubMedCrossRef

89.

Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, et al. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med. 2015;191(10):1166–75. https://doi.org/10.1164/rccm.201408-1475OC.PubMedCrossRef

90.

Pastorino U, Rossi M, Rosato V, Marchiano A, Sverzellati N, Morosi C, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21(3):308–15. https://doi.org/10.1097/CEJ.0b013e328351e1b6.PubMedCrossRef

91.

van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009;361(23):2221–9. https://doi.org/10.1056/NEJMoa0906085.PubMedCrossRef

92.

Ru Zhao Y, Xie X, de Koning HJ, Mali WP, Vliegenthart R, Oudkerk M. NELSON lung cancer screening study. Cancer Imaging 2011;11 Spec No A:S79–84. https://doi.org/10.1102/1470-7330.2011.9020.

93.

Pedersen JH, Ashraf H. Implementation and organization of lung cancer screening. Ann Transl Med. 2016;4(8):152. https://doi.org/10.21037/atm.2016.03.59.PubMedPubMedCentralCrossRef

94.

Wu GX, Raz DJ, Brown L, Sun V. Psychological burden associated with lung cancer screening: a systematic review. Clin Lung Cancer. 2016;17(5):315–24. https://doi.org/10.1016/j.cllc.2016.03.007.PubMedPubMedCentralCrossRef

Title: The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring
Authors: Jillian Wilhelmina Paulina Bracht
Clara Mayo-de-las-Casas
Jordi Berenguer
Niki Karachaliou
Rafael Rosell
Publication date: 01-09-2018
Publisher: Springer US
Published in: Current Oncology Reports / Issue 9/2018
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-018-0720-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 9/2018

Endoscopic Treatment of Early-Stage Esophageal Cancer

Immune Checkpoint Inhibitor Toxicity

Adoptive Cell Therapy in Treating Pediatric Solid Tumors

Updated Guidelines for the Treatment of Acquired Aplastic Anemia in Children

Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks

Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer